NEW YORK (July 23, 2025) – Holland & Knight advised Waldencast plc (NASDAQ: WALD) in the acquisition of Novaestiq Corp., a growth-oriented aesthetic and medical dermatological innovations company, as well as the U.S. rights to the Saypha® line of hyaluronic acid injectable gels. The transaction was announced on July 23.
Based in London, Waldencast is a global multi-brand beauty and wellness platform. The strategic acquisition is set to expand Waldencast's Obagi Medical offerings beyond medical-grade skincare by entering into the dermal filler market in the U.S., with the new business operating under Obagi Medical.
Holland & Knight Partners Amy Leder and Scott Syverson led the Firm's representation of Waldencast, along with Partners Bryan Gadol and Robin Feiner and Associates Nicole Lamanna and Ferrell Littlejohn (M&A). They were assisted by Partner Charles Weiss and Associate Leonie Huang (Intellectual Property); Associate Sara Klock (Regulatory); Partner Eric Rubin and Associate Patrick Burri (Executive Compensation & Benefits); and Partner Marc Druckman (Representations and Warranties Insurance).
More information on the transaction can be found here.
Recently recognized as the Private Equity Law Firm of the Year by the Global M&A Network, Holland & Knight regularly ranks among the leading M&A and private equity law firms in reputable, benchmarking league tables published by Bloomberg, LSEG, Mergermarket, PitchBook and The Deal. Through the HK Deal Flow℠ program, Holland & Knight facilitates deal leads for clients and prospective clients by matching acquisition or capital raising opportunities with buyers and investors.